25,729 articles
Zafirlukast
Zafirlukast (Accolate) is an oral leukotriene receptor antagonist for chronic asthma prophylaxis in patients 5 years and older; FDA approved 1996, dosed 20 mg twice daily, with hepatotoxicity and warfarin interaction warnings.
Zalcitabine
Zalcitabine (ddC, 2′,3′-dideoxycytidine, Hivid) was Roche's nucleoside reverse transcriptase inhibitor, FDA-approved in 1992 with zidovudine for advanced HIV; limited by peripheral neuropathy and stomatitis, discontinued December 31, 2006.
Zaleplon
Zaleplon, originally sold as Sonata and also marketed as Starnoc, is a short-acting nonbenzodiazepine hypnotic drug used for short-term treatment of insomnia, distinguished by an elimination half-life of about one hour.
Zalunfiban
Zalunfiban (RUC-4, Disaggpro) is an investigational subcutaneous glycoprotein IIb/IIIa inhibitor for STEMI given at first medical contact; the phase 3 CELEBRATE trial (2,467 patients) showed improved artery patency and fewer 30-day adverse outcomes without excess severe bleeding.
Zalutumumab
Zalutumumab (HuMax-EGFr, clone 2F8), a fully human IgG1 anti-EGFR monoclonal antibody from Genmab for head and neck cancer; development suspended in 2011 after phase 3 trials showed no overall survival benefit.
Zamerovimab and mazorelvimab (SYN023)
Zamerovimab and mazorelvimab (SYN023, 克瑞毕) is a Chinese-approved humanized monoclonal antibody cocktail of CTB011 and CTB012 for passive immunization after category III rabies exposure, given at 0.3 mg/kg with rabies vaccine; approved by NMPA June 4, 2024.
Zandelisib
Zandelisib (ME-401, PWT-143), an oral selective PI3Kδ inhibitor by MEI Pharma and Kyowa Kirin for B-cell lymphomas; intermittent dosing gave 73% ORR in TIDAL, but development was discontinued in 2023.
Zangfu
Zangfu (脏腑), also known as Zang-fu viscera or Zang Fu theory, is the traditional Chinese medicine system of five Yin zang organs and six Yang fu organs.
Zanolimumab
Zanolimumab (HuMax-CD4, MDX-016) is a fully human IgG1 anti-CD4 monoclonal antibody for T-cell lymphoma; phase 2 CTCL responses reached 56% at high dose, but development was discontinued and rights licensed to TenX Biopharma in 2010.
Zanubrutinib
Zanubrutinib (Brukinsa, BGB-3111) is an oral second-generation covalent BTK inhibitor discovered by BeiGene, FDA-approved from 2019 for MCL, WM, MZL, CLL/SLL, and FL with obinutuzumab, with superior efficacy and lower atrial fibrillation rates than ibrutinib in ALPINE.
Zanzalintinib
Zanzalintinib (XL092) is Exelixis's oral multitargeted kinase inhibitor blocking c-Met, VEGFR2, AXL, and MER, in phase 3 trials for metastatic colorectal, renal cell, and neuroendocrine cancers; FDA PDUFA date December 3, 2026.
Zaoren Ningxin dripping pills
Zaoren Ningxin dripping pills (枣仁宁心滴丸, formerly Anshen dripping pills) are a TCM class 1.1 innovative drug from Tasly, approved by NMPA on 5 June 2026 for insomnia of the heart-liver blood deficiency pattern, derived from Zhang Boli's modification of the Suanzaoren decoction.
Zasocitinib
Zasocitinib (TAK-279, NDI-034858) is Takeda's investigational oral, allosteric, highly selective TYK2 inhibitor, AI-designed with over 1 million-fold TYK2 selectivity; it beat deucravacitinib in a phase 3 psoriasis head-to-head trial (PASI 100 36.5% vs 13.9%).
Zatolmilast
Zatolmilast (BPN14770; also S-898270) is an investigational oral PDE4D inhibitor developed for Fragile X syndrome, discovered by Tetra Therapeutics, which Shionogi acquired in 2020; it is not yet approved.
Zavegepant
Zavegepant (Zavzpret) is a Pfizer CGRP receptor antagonist nasal spray approved by FDA March 9, 2023 for acute migraine with or without aura in adults; 10 mg single spray, ~5% bioavailability, NNT 11 for 2-hour pain freedom.
Zebra body myopathy
Zebra body myopathy (ORPHA:97240) is an extremely rare benign congenital myopathy with neonatal hypotonia and weakness, fewer than ten reported cases, zebra-body inclusions on muscle biopsy, and ACTA1 mutations implicated.
Zeigarnik effect
Zeigarnik effect: proposed better memory for interrupted, unfinished than completed tasks, named after Bluma Zeigarnik (1927, Psychologische Forschung). A 2025 meta-analysis found no reliable recall advantage (ratio 0.99, dz 0.15); the related Ovsiankina resumption effect (~67%) is better supported.
Zeitschrift für medizinische Physik
Zeitschrift für medizinische Physik (Journal of Medical Physics), quarterly Elsevier journal founded 1990, official organ of the German, Austrian, and Swiss medical physics societies; open access since 2022, 2025 impact factor 4.7.
Zelé2021 trial
Zelé2021 (NCT06275347) was a 12-week Mexican randomized double-blind trial comparing the Zélé method very-low-calorie low-fat ketogenic diet with a standard low-calorie diet in class I obesity, showing greater fat-predominant weight loss.
Zellweger syndrome
Zellweger syndrome, the severe form of Zellweger spectrum disorder (ZSD, cerebrohepatorenal syndrome), is an autosomal recessive peroxisome biogenesis disorder caused by PEX gene defects, mainly PEX1, causing hypotonia, seizures, and early death.
Zengye Chengqi Decoction
Zengye Chengqi Decoction (增液承气汤), a Qing-era formula from Wu Jutong's Wenbing Tiaobian (1798): five drugs, xuanshen, maidong, shengdi, dahuang, mangxiao, treating heat-bound constipation with yin deficiency by the "increase water to float the boat" method.
Zenker's diverticulum
Zenker's diverticulum, also called a pharyngeal or pharyngoesophageal diverticulum, is an outpouching at the junction of the pharynx and esophagus that causes difficulty swallowing and regurgitation of food in elderly men.
Zenocutuzumab
Zenocutuzumab-zbco (Bizengri, MCLA-128) is a bispecific HER2/HER3 antibody by Merus and Partner Therapeutics for NRG1 fusion-positive NSCLC, pancreatic adenocarcinoma, and cholangiocarcinoma; FDA-approved 2024 and 2026.
Zeprumetostat tablets
SHR2554 (Zeprumetostat, 泽美妥司他) is Hengrui's oral EZH2 inhibitor, conditionally approved in China for relapsed/refractory peripheral T-cell lymphoma after a phase 1 trial showing 43% ORR at 350 mg twice daily, and out-licensed to Treeline Biosciences outside Greater China.
Zero-fluoroscopy catheter ablation
Zero-fluoroscopy catheter ablation is a cardiac electrophysiology technique that replaces X-ray guidance with electroanatomic mapping and intracardiac echocardiography, avoiding radiation and proving as safe and effective as conventional ablation.
Zevorcabtagene autoleucel (zevor-cel, CT053)
Zevorcabtagene autoleucel (zevor-cel, CT053; 泽沃基奥仑赛注射液, brand 赛恺泽) is CARsgen's fully human BCMA-directed autologous CAR T-cell therapy, conditionally approved in China February 2024 for relapsed/refractory multiple myeloma after three prior lines, with fixed 1.5×10^8 cell dosing.
Zexie Tang
Zexie Tang (泽泻汤, Alisma Decoction) is a two-herb classical Chinese formula from Zhang Zhongjing's Jingui Yaolue: alisma 5 liang plus atractylodes 2 liang, for vertigo from fluid retention, with diuretic, lipid-lowering, and anti-inflammatory actions.
Zhengzhi Zhunsheng
证治准绳 (Zhengzhi Zhunsheng, Criterion of Diagnosis and Treatment), also called Liuke Zhunsheng, a 44-juan Ming clinical medical encyclopedia by Wang Kentang (1549–1613), first printed 1602–1608, covering miscellaneous diseases, cold damage, surgery, pediatrics, and gynecology.
Zhenwu decoction
真武汤 (Zhenwu decoction, Zhenwu tang), a classical Chinese medicine formula from the Shanghan Lun with fuling, shaoyao, baizhu, fuzi, and shengjiang; warms yang and promotes urination, mainly studied for chronic heart failure.
Zhishi Total Flavonoids Tablets (Fructus Aurantii Immaturus total flavonoids)
Zhishi Total Flavonoids Tablets (枳实总黄酮片, Aulantai) is a class 1.2 innovative TCM from immature bitter orange, approved by NMPA in October 2023 for functional dyspepsia, made by Jiangxi Qingfeng and reimbursed nationally since 2025.